Nsaid use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The liver cancer pooling project

Cancer Prevention Research

Volumn 8, Issue 12, 2015, Pages 1156-1162

  Petrick, Jessica L ^a   Sahasrabuddhe, Vikrant V ^a,b   Chan, Andrew T ^c,d   Alavanja, Michael C ^a   Beane Freeman, Laura E ^a   Buring, Julie E ^c,e   Chen, Jie ^a   Chong, Dawn Q ^d,f   Freedman, Neal D ^a   Fuchs, Charles S ^g   Gaziano, John Michael ^c,h   Giovannucci, Edward ^e   Graubard, Barry I ^a   Hollenbeck, Albert R ⁿ   Hou, Lifang ⁱ   Jacobs, Eric J ^j   King, Lindsay Y ^c,d   Koshiol, Jill ^a   Lee, I Min ^c,e   Linet, Martha S ^a   Palmer, Julie R ^k   Purdue, Mark P ^a   Rosenberg, Lynn ^k   Schairer, Catherine ^a   Sesso, Howard D ^c,e   Sigurdson, Alice J ^a   Wactawski Wende, Jean ^l   Zeleniuch Jacquotte, Anne ^m   Campbell, Peter T ^j   McGlynn, Katherine A ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j AMERICAN CANCER SOCIETY   (United States)

^k BOSTON UNIVERSITY   (United States)

^l UNIVERSITY AT BUFFALO   (United States)

^m NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BILE DUCT CARCINOMA; BODY MASS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MEGADOSE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TREATMENT DURATION; BILE DUCT TUMOR; LIVER TUMOR; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84952047687     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0126     Document Type: Article

References (46)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975-2011, Bethesda, MD: National Cancer Institute. [cited 2014 Apr] Available from: http://seer.cancer.gov/csr/1975-2011/, based on November 2013 SEER data submission, posted to the SEER web site.
2. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. [cited 2014 Jun 2] Available from: http://globocan.iarc.fr.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
4. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-43, vii-x.
5. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
6. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62:118-28.
7. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
8. Spangenberg HC, Thimme R, Blum HE. Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:425-33.
9. Altekruse SF, Devesa SS, Dickie LA, McGlynn KA, Kleiner DE. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J Registry Manag 2011;38:201-5.
10. Ambade A, Mandrekar P. Oxidative stress and inflammation: Essential partners in alcoholic liver disease. Int J Hepatol 2012;2012:853175.
11. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012;57:69-76.
12. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
13. Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci 2011;1:5.
14. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol 2009;10:501-7.
15. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: A summary review to 2007. Recent Results Cancer Res 2009;181:231-51.
16. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
17. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: An overview. Cancer Prev Res 2012;5:164-78.
18. Shebl FM, Hsing AW, Park Y, Hollenbeck AR, Chu LW, Meyer TE, et al. Nonsteroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study. PLoS One 2014;9: E114633.
19. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15.
20. Fodera D, D'Alessandro N, Cusimano A, Poma P, Notarbartolo M, Lampiasi N, et al. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci 2004;1028:440-9.
21. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: Evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003;38:756-68.
22. Cervello M, Foderaa D, Florena AM, Soresi M, Tripodo C, D'Alessandro N, et al. Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol 2005;11:4638-43.
23. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000;9: 119-23.
24. Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Nat Cancer Inst 2012;104:1808-14.
25. McGlynn KA, Sahasrabuddhe VV, Campbell PT, Graubard BI, Chen J, Schwartz LM, et al. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among U.S.women: Results from the Liver Cancer Pooling Project. Br J Cancer 2015;112 Suppl:1266-72.
26. Kleinbaum D. Logistic regression: A self-learning text second ed. New York: Springer; 2002.
27. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
28. Dales LG, Ury HK. An improper use of statistical significance testing in studying covariables. Int J Epidemiol 1978;7:373-5.
29. Kleinbaum DG, Klein M. Survival analysis: A self-learning text. 3rd ed. New York: Springer; 2012.
30. Machin D, Cheung YB, Parmar MKB, Parmar MKB. Survival analysis: A practical approach. 2nd ed. Chichester, England; Hoboken, NJ: Wiley; 2006.
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
32. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997;40:1580-6.
33. Food, Drug Administration USDoH, Human S. Concomitant use of ibuprofen and aspirin. J Pain Palliat Care Pharmacother 2007;21:73-4.
34. Cervello M, Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 2006;12:5113-21.
35. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
36. Hohlfeld T, Saxena A, Schror K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs-pharmacological mechanisms and clinical relevance. Thromb Haemost 2013;109: 825-33.
37. Kern MA, Schubert D, Sahi D, Schoneweiss MM, Moll I, Haugg AM, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002;36:885-94.
38. Vaish V, Sanyal SN. Chemopreventive effects of NSAIDs on cytokines and transcription factors during the early stages of colorectal cancer. Pharmacol Rep 2011;63:1210-21.
39. Daniel N, Goulet J, Bergeron M, Paquin R, Landry P. Antiplatelet drugs: is there a surgical risk? J Can Dent Assoc 2002;68:683-7.
40. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 2009;183:2089-96.
41. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A 2012;109:E2165-72.
42. Kim AK, Dziura J, Strazzabosco M. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: The egg of columbus or another illusion? Hepatology 2013;58:819-21.
43. McGlynn KA, Divine GW, Sahasrabuddhe VV, Engel LS, VanSlooten A, Wells K, et al. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol 2014;38:523-7.
44. McGlynn KA, Hagberg K, Chen J, Graubard BI, London WT, Jick S, et al. Statin use and risk of primary liver cancer in the clinical practice research datalink. J Natl Cancer Inst 2015;107.pii: djv009.
45. Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014;11:45-54.
46. Garcia-Albeniz X, Chan AT. Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol 2011;25:461-72.